NRC HEALTH NRC
NRC HEALTH (NRC) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the distress zone. It pays a dividend yielding 2.34% (safety: n/a).
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Services · percentile among 982 companies
Percentile vs other Services companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | -0.122 |
| Retained earnings / assets | -0.128 |
| EBIT / assets | 0.167 |
| Equity / liabilities | 0.116 |
Sector peers · similar-size Services companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| NRC | NRC HEALTH | 3/9 | 0.03 | — | -4% |
| OABI | OmniAb, Inc. | 1/9 | 6 | — | -29.3% |
| BIAF | bioAffinity Technologies, Inc. | 3/9 | — | — | — |
| ABSI | Absci Corp | 2/9 | -1.9 | — | — |
| ISPC | iSpecimen Inc. | 3/9 | — | — | — |
| ONMD | OneMedNet Corp | 5/9 | — | — | — |
| VSBC | VITASPRING BIOMEDICAL CO. LTD. | 4/9 | — | — | — |
About NRC HEALTH
NRC Health provides analytics and insights to measure and improve patient and employee experience for healthcare organizations in the United States. The company offers market experience solutions, a subscription-based services for improved tracking of awareness, perception, and consistency of healthcare brands; assessment of differentiators; and segmentation tools to evaluate the needs, wants, and behaviors of communities through assessments. It also provides patient experience solutions, a cross-continuum multi-mode digital platform that collects and measures data to improve patient experience, engagement, and loyalty; employee experience solutions, which combines health care with technology comprising engagement, pulse, lifecycle, culture of safety, and magnet RN satisfaction; and consumer experience solution that offers online reputation solutions, community insights, and cross-journey listening through nGage. In addition, the company offers Huey, an AI engine built for Human Understanding that serves as a healthcare experience management companion; and governance solutions provided through national conferences, publications, advisory services, and an online portal for not-for-profit health system boards of directors, executives, and physician leadership. Further, it provides patient experience, service recovery, care transitions, employee engagement, reputation management, rounding, and brand loyalty. The company was formerly known as National Research Corporation and changed its name to NRC Health April 2026. The company was founded in 1981 and is headquartered in Lincoln, Nebraska.
FAQ
Is NRC financially healthy?
NRC HEALTH's Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does NRC pay a dividend, and is it safe?
Yes. NRC HEALTH pays a dividend yielding about 2.34% with a None payout ratio, rated “n/a” for safety.
Is NRC overvalued or undervalued?
NRC HEALTH trades at about 0.4× trailing earnings — below its 10-year norm (10-year range 0.4×–53.7×, median 31.2×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for NRC?
The average Wall-Street price target for NRC HEALTH is $23.00, about 11.6% above the recent price, from 1 analysts (consensus: buy).
Is NRC a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on NRC HEALTH: a Piotroski F-score of 3/9, an Altman Z″ in the distress zone, a dividend yield of 2.34%. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.